Wallace's career has centred on the use of gaseous mediators to treat inflammation, particularly intestinal injury and dysfunction.
Wallace has published more than 500 peer-reviewed papers and is among the top 0.5 percent of biomedical scientists worldwide in citations (> 42,000), with a current Hirsch index of 110.
[5] From 1989 to 2009, Wallace was a professor of Pharmacology and Therapeutics at the University of Calgary, where he held the Canada Research Chair in Inflammation.
[7] Wallace co-founded NicOx in 1996, creating the first pharmaceutical company to commercialize gaseous mediator technology.
[8] Dr Wallace was chair of NicOx's Scientific Advisory Board from 1996 to 2003, which included Nobel Laureates Bengt Samuelsson and Louis Ignarro.